SAB Biotherapeutics, Inc. Warrant
SABSW$0.02 0.00 (0.00%)
Company News
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
SAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.
SILQFi Launches Omni Following Acquisition of OXO
SILQFi has launched Omni, a new financial platform for small businesses, after acquiring OXO. The platform integrates point-of-sale, procurement, payments, and credit access to streamline merchant workflows and improve capital access in Saudi Arabia.
